Oncobiologics (NASDAQ:OTLK – Get Free Report) and Equillium (NASDAQ:EQ – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.
Profitability
This table compares Oncobiologics and Equillium’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oncobiologics | N/A | N/A | -254.82% |
| Equillium | N/A | -37.33% | -35.07% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Oncobiologics and Equillium, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncobiologics | 1 | 2 | 2 | 0 | 2.20 |
| Equillium | 1 | 1 | 8 | 2 | 2.92 |
Oncobiologics presently has a consensus price target of $5.20, indicating a potential upside of 1,174.82%. Equillium has a consensus price target of $7.12, indicating a potential upside of 547.73%. Given Oncobiologics’ higher possible upside, equities research analysts clearly believe Oncobiologics is more favorable than Equillium.
Volatility and Risk
Oncobiologics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Equillium has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500.
Insider & Institutional Ownership
11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 27.0% of Equillium shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by insiders. Comparatively, 17.8% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Oncobiologics and Equillium”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncobiologics | -$1.16 million | -85.35 | -$62.42 million | ($0.77) | -0.53 |
| Equillium | N/A | N/A | -$22.40 million | ($0.18) | -6.11 |
Equillium has higher revenue and earnings than Oncobiologics. Equillium is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.
Summary
Equillium beats Oncobiologics on 10 of the 13 factors compared between the two stocks.
About Oncobiologics
Oncobiologics, Inc. changed its name to Outlook Therapeutics, Inc. in 2018 and trades under the symbol OTLK. The biotechnology company focuses on developing and commercializing treatments for eye diseases. Its lead product, Lytenava (bevacizumab gamma), is an ophthalmic formulation of bevacizumab developed to treat neovascular age-related macular degeneration, also known as wet AMD. The company has pursued regulatory approvals and commercialization of the treatment in the United States and Europe.
About Equillium
Equillium is a biotechnology company focused on developing medicines that target immune pathways involved in autoimmune and inflammatory diseases. Its research has centered on treatments for conditions with significant unmet medical needs. The company’s leading program has been itolizumab, a monoclonal antibody that targets CD6, an immune-cell protein. Equillium obtained development and commercialization rights to itolizumab from India-based Biocon for several markets, including the United States, Canada, Australia and New Zealand.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.
